Psilocybin vs Escitalopram: What the Six-Month Follow-Up Adds

Psilocybin findings can be promising without answering every patient question. This source-based guide examines psilocybin versus escitalopram while separating supervised research from claims about personal benefit or commercial access.

The original primary result matters

The 2021 randomized comparison enrolled 59 people with major depressive disorder and provided psychological support to both groups. The prespecified primary depression outcome did not differ significantly at six weeks. Secondary outcomes favoring psilocybin needed caution because of multiple comparisons and did not overturn that primary result.

What the 2024 follow-up added

Both groups maintained depression improvement at six months without a statistically significant between-group symptom-severity difference. Some secondary functioning and wellbeing measures favored the original psilocybin group. Those outcomes are interesting because symptom scales do not capture all recovery, but they differ from proof of superiority on the main outcome.

Observation is not continuous control

The follow-up was observational. Subsequent treatment and experiences can influence outcomes after initial randomization. Authors stated safety during follow-up was not assessed, so it cannot support comprehensive long-term safety comparisons. Small samples and masking difficulties also constrain interpretation. A nonsignificant difference is not proof of equivalence, which requires an appropriate design.

What stronger evidence would need

Larger longer trials should assess symptoms, function, subsequent care and harms together. Keep original assignment separate from the actual care received later. These results concern a supervised package, not commercial superiority over antidepressants. Medication changes require oversight. The useful message is sustained improvement with uncertainty, not a contest with a clear winner, and secondary findings should remain exploratory until adequately confirmed.

This article is informational, not an individualized treatment recommendation. A qualified clinician can interpret the evidence alongside your diagnosis, history and existing care. Do not alter prescribed treatment based on a study summary.

Sources

• Carhart-Harris et al., 2021: Randomized trial
• Erritzoe et al., 2024: Six-month follow-up

This article is for general information, not individual medical advice. Illustration is AI-generated and does not depict actual study participants.